On May 12, 2021 Regen Biopharma, Inc. (the “Company”) executed a consulting agreement with Biotech Research Group Corporation (the “Consultant”), an FDA Specialist Group and Global Regulatory and Scientific Experts, for the purpose of review and guidance with regard to the planned reinstatement of the Company’s inactive Investigational New Drug applications (INDs) #15376 and #16200 filed with the United States Food and Drug Administration (“FDA”). The securing of the services to be provided to the Company pursuant to this consulting agreement marks the first step taken by the Company with regard to activating the Company’s currently inactive applications to initiate clinical trials.
News 
Market Data 
Discover 
